Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-015359
Filing Date
2025-02-06
Accepted
2025-02-06 15:58:01
Documents
1
Period of Report
2025-02-04

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 5898
  Complete submission text file 0000950170-25-015359.txt   7379
Mailing Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203
Business Address 1222 DEMONBREUN STREET SUITE 2000 NASHVILLE TN 37203 6157247755
Revance Therapeutics, Inc. (Issuer) CIK: 0001479290 (see all company filings)

EIN.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O AERIE PHARMACEUTICALS, INC. 4301 EMPEROR BLVD., SUITE 400 DURHAM NC 27703
Business Address
Hollander David (Reporting) CIK: 0001793796 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36297 | Film No.: 25597217